首页> 美国卫生研究院文献>Research and Practice in Thrombosis and Haemostasis >Type 2A von Willebrand disease and systemic sclerosis: Vonicog alfa reduced gastrointestinal bleeding
【2h】

Type 2A von Willebrand disease and systemic sclerosis: Vonicog alfa reduced gastrointestinal bleeding

机译:2A型von Willebrand疾病和全身硬化症:Vonicog Alfa降低了胃肠道出血

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Von Willebrand disease (VWD) is a bleeding disorder caused by qualitative or quantitative defects of von Willebrand factor (VWF). This case report of a patient with systemic sclerosis and gastrointestinal bleeding from angiodysplasias seeks to address the key clinical question of a useful diagnostic and therapeutic approach in this setting. The extent of vascular malformations and the frequency of bleeding episodes were unusually severe, and we reached a diagnosis of inherited type 2A VWD. After an insufficient effect of treatment with factor VIII (FVIII)/VWF, prophylactic administration of vonicog alfa, a recombinant VWF preparation without FVIII, was initiated. This therapy led to a substantial reduction of transfusion requirements and the improvement of angiodysplasias. In refractory gastrointestinal bleeding, hemostaseological evaluation is crucial, as inherited disorders of hemostasis may go unnoticed, especially in patients with underlying autoimmune diseases, where complications may be ascribed to the underlying disease.
机译:Von Willebrand疾病(VWD)是由Von Willebrand因子(VWF)的定性或定量缺陷引起的出血障碍。从血管无血症平均具有全身硬化和胃肠道出血的患者的病例报告旨在解决这种环境中有用的诊断和治疗方法的关键临床问题。血管畸形的程度和出血发作的频率异常严重,我们达到了继承的2A VWD的诊断。在用因子VIII(FVIII)/ VWF的治疗效果不足之后,启动了副血清ALFA的预防施用,未经FVIII的重组VWF制剂。这种疗法导致输血要求的大幅降低和血管无血糖的改善。在难治性胃肠道出血中,止血态评估至关重要,因为止血的遗传紊乱可能会被忽视,特别是在潜在的自身免疫疾病患者中,并发症可能归因于潜在的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号